Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 6 Combination therapy for HCC

Published byἈληκτώ Μελετόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 6 Combination therapy for HCC"— Presentation transcript:

1 Figure 6 Combination therapy for HCC
Figure 6 | Combination therapy for HCC. Combination of internal and systemic approaches avoids the toxicity risk of concurrent intravenous administration of several mAbs. Abbreviations: CTLA-4, cytotoxic T-lymphocyte protein 4; HCC, hepatocellular carcinoma; mAb, monoclonal antibody; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1. Prieto, J. et al. (2015) Immunological landscape and immunotherapy of hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 6 Combination therapy for HCC"

Similar presentations

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Volume 71, Issue 2, Pages (February 2017)

Volume 71, Issue 2, Pages (February 2017)
Figure 5 Dendritic cells in liver inflammation

Figure 5 Dendritic cells in liver inflammation
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Figure 6 Injection of mesenchymal stem cells in perianal fistulas
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 2 Neoantigen presentation in the tumour microenvironment
Figure 2 A stage-based approach to the treatment of NAFLD

Figure 2 A stage-based approach to the treatment of NAFLD
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 7 Clinical options for HCC therapy

Figure 7 Clinical options for HCC therapy
Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 1 Organs involved in coeliac-disease-associated autoimmunity
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Classification of immunotherapies

Figure 5 Classification of immunotherapies
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Similar presentations

Ads by Google